Clinical Trial Update: BGJ398 in Non-Muscle-Invasive Urothelial Carcinoma of the Bladder [NA]

View source ↗

Summary

A clinical trial evaluating BGJ398 (erdafitinib), a FGFR inhibitor, in non-muscle-invasive urothelial carcinoma of the bladder has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Non-muscle-invasive Urothelial Carcinoma

Drugs mentioned

• BGJ398 (erdafitinib) (erdafitinib)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Bladder Cancer, Non-Muscle-Invasive Urothelial Carcinoma | NA | Status: COMPLETED